Inventor
LOVEY RAYMOND G
US32 patents
⚠️ This page may combine multiple inventors who share the name “LOVEY RAYMOND G”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCHERING CORP
27 patentsUS6911428B2Jun 28, 2005
Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
SCHERING CORP124 citations98
US6800434B2Oct 5, 2004
Peptides as NS3-serine protease inhibitors of hepatitis C virus
SCHERING CORP89 citations97
US6403564B1Jun 11, 2002
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
SCHERING CORP122 citations97
US6277830B1Aug 21, 2001
5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
SCHERING CORP120 citations97
US5661151AAug 26, 1997
Tetrahydrofuran antifungals
SCHERING CORP69 citations96
US4358453ANov 9, 1982
1,2,4-Triazolo[4,3-a]pyridines
SCHERING CORP59 citations96
US5714490AFeb 3, 1998
Tetrahydrofuran antifungals
SCHERING CORP37 citations93
US5693626ADec 2, 1997
Tetrahydrofuran antifungals
SCHERING CORP24 citations93
US6894072B2May 17, 2005
Compounds as NS3-serine protease inhibitors of hepatitis C virus
SCHERING CORP59 citations92
US5403937AApr 4, 1995
Process for preparing intermediates for the synthesis of antifungal agents
SCHERING CORP21 citations92
US4464372AAug 7, 1984
Imidazo[1,2-b]pyridazines
SCHERING CORP44 citations92
US5710154AJan 20, 1998
Tetrahydrofuran antifungals
SCHERING CORP13 citations74
US5703236ADec 30, 1997
Tetrahydrofuran antifungals
SCHERING CORP11 citations74
US5703079ADec 30, 1997
Tetrahydrofuran antifungals
SCHERING CORP16 citations74
US4507294AMar 26, 1985
Imidazo[1,2-a]pyrazines
SCHERING CORP18 citations74
US4409226AOct 11, 1983
Imidazo[1,5-a]pyridines
SCHERING CORP15 citations74
US7115578B2Oct 3, 2006
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
SCHERING CORP8 citations73
US5925648AJul 20, 1999
Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
SCHERING CORP16 citations73
US5883097AMar 16, 1999
Soluble azole antifungal salt
SCHERING CORP9 citations73
US4737508AApr 12, 1988
1-aryl-1-(1H-azol-1-ylalkyl)-1,3-dihydroisobenzofurans, related derivatives and pharmaceutical compositions thereof useful as antifungals
SCHERING CORP11 citations73
US6924270B2Aug 2, 2005
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
SCHERING CORP11 citations71
US4361567ANov 30, 1982
Treatment of peptic ulcer disease
SCHERING CORP5 citations63
US4358454ANov 9, 1982
1,3,4-Triazolo[1,5-a]pyridines
SCHERING CORP6 citations63
US6673775B2Jan 6, 2004
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
SCHERING CORP4 citations62
US4877801AOct 31, 1989
1-Aryl-1-(1H-azol-1-ylalkyl)-1,3-dihydroisobenzofurans, related derivatives and pharmaceutical compositions thereof useful as antifungals
SCHERING CORP4 citations62
US5698557ADec 16, 1997
Hydroxy-substituted antifungals
SCHERING CORP0 citations52
US7595299B2Sep 29, 2009
Peptides as NS3-serine protease inhibitors of hepatitis C virus
SCHERING CORP0 citations51
DENDREON CORP
3 patentsUS7012066B2Mar 14, 2006
Peptides as NS3-serine protease inhibitors of hepatitis C virus
DENDREON CORP176 citations98
US7244721B2Jul 17, 2007
Peptides as NS3-serine protease inhibitors of hepatitis C virus
DENDREON CORP80 citations97
US7169760B2Jan 30, 2007
Peptides as NS3-serine protease inhibitors of hepatitis C virus
DENDREON CORP88 citations97